The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort

• Published in: Urologic oncology 2020-09, Vol.38 (9), p.739.e9-739.e15
• Main Authors: Janisch, Florian, Hillemacher, Tobias, Fuehner, Constantin, D'Andrea, David, Meyer, Christian P., Klotzbücher, Thomas, Kienapfel, Christina, Vetterlein, Malte W., Kimura, Shoji, Abufaraj, Mohammad, Dahlem, Roland, Shariat, Shahrokh F., Fisch, Margit, Rink, Michael
• Format: Article
• Language: English
• Subjects: Cytoreductive nephrectomy; Metastatic renal cell carcinoma; Tyrosine-kinase inhibitor
• ISSN: 1078-1439; 1873-2496
• DOI: 10.1016/j.urolonc.2020.04.033

•In this real-world investigation we assess the impact of cytoreductive nephrectomy (CN) prior to tyrosine kinase inhibitor (TKI) therapy in metastatic renal cell carcinoma patients.•Overall, we found no difference for all endpoints between CN + TKI vs. TKI only treatment.•However, patients in some subgroups benefitted from CN.•Clear cell histology predicted improved progression-free survival and cancer-specific survival after CN. Tyrosine kinase inhibitor therapy (TKI) has changed the treatment paradigm of metastatic renal cell carcinoma (mRCC). The recent CARMENA and SURTIME trials challenged the role of the cytoreductive nephrectomy (CN). To assess the impact of CN prior to TKI therapy in patients with mRCC in a real-world setting. Overall, 262 consecutive patients with mRCC were treated with CN plus TKI or TKI only at our institution between 2000 and 2016. Patients with prior immunotherapy or metastasectomy were excluded. Multiple imputation and inverse probability of treatment weighting (IPTW) were performed to account for missing values and imbalances between the treatment groups, respectively. Unadjusted and adjusted Kaplan-Meier estimates were used to determine differences in progression-free (PFS), overall (OS), and cancer-specific survival (CSS). Overall, 104 (40%) patients received CN before TKI treatment. Most frequent first line therapy was Sunitinib (66%), followed by Sorafenib (20%) and Pazopanib (10%). After adjustment with IPTW, there was no difference in PFS, CSS, and OS (all P > 0.05) between the treatment groups. In subgroup analyses, CSS was improved when CN was performed in patients with sarcomatoid features and clear cell histology (P = 0.04 and P = 0.03) and PFS was improved in patients with clear cell histology when CN was performed [0.04]). CN did not improve OS in any subgroup analysis. The role of CN remains controversial. We found no difference in survival outcomes between patients treated with and without CN before TKI therapy. However, CN was associated with improved survival in specific patient subgroups. Tailored, individualized treatment is key to further improve oncological outcomes for mRCC.